Literature DB >> 23250484

Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.

Tomoaki Tatsumi1, Shuichi Yamamoto, Juntaro Uehara, Takeshi Sugawara, Takayuki Baba, Masayuki Inoue, Hiroko Hata, Yoshinori Mitamura.   

Abstract

BACKGROUND: To compare the therapeutic effects of panretinal photocoagulation (PRP) combined with intravitreal bevacizumab (IVB) and cryoretinopexy (CR-IVB) to that of PRP combined with IVB alone in eyes with neovascular glaucoma (NVG).
DESIGN: Retrospective, consecutive, case-control study.
METHODS: The medical records of 102 eyes of 96 patients with NVG due to proliferative diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome were reviewed. The mean age of the patients was 59.6 ± 11.5 years, with a range of 34 to 84 years. Patients received either 1.25 mg/0.05 ml of IVB combined with 360° of cryotherapy of the peripheral retina (CR-IVB subgroup) or IVB alone (IVB alone subgroup) as adjunctive treatments to PRP. The patients were followed for at least 12 months. Fifty-four eyes of 49 patients had open-angle NVG; 30 of these eyes were treated by CR-IVB, and 24 eyes by IVB alone. Forty-eight eyes of 48 patients had angle-closure NVG; 22 of these eyes were treated by CR-IVB, and 26 eyes were by IVB alone. Failure was defined as a postoperative intraocular pressure (IOP) >21 mmHg for two consecutive follow-up visits, or the need of additional surgery such as trabeculectomy or diode laser cycloablation. The differences in the success rates between the CR-IVB and IVB alone subgroups for the eyes with open-angle and closed-angle NVG were compared.
RESULTS: The success rate at 12 months in eyes with open-angle NVG was 80.0% in the CR-IVB subgroup and 41.7% in the IVB alone subgroup (P = 0.0096). In eyes with angle-closure NVG, the success rate at 12 months was 22.7% in the CR-IVB subgroup and 0% in the IVB-alone subgroup (P = 0.030).
CONCLUSION: The significantly better IOP control after PRP combined with cryotherapy and IVB than after PRP with IVB alone indicates that cryotherapy enhances the effectiveness of PRP for neovascular glaucoma for at least 1 year.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250484     DOI: 10.1007/s00417-012-2236-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  20 in total

1.  Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

Authors:  Robert L Avery
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

2.  Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.

Authors:  Jayter Silva Paula; Rodrigo Jorge; Rogério Alves Costa; Maria de Lourdes V Rodrigues; Ingrid U Scott
Journal:  Acta Ophthalmol Scand       Date:  2006-08

3.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

4.  Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.

Authors:  Milko E Iliev; Diego Domig; Ute Wolf-Schnurrbursch; Sebastian Wolf; Gian-Marco Sarra
Journal:  Am J Ophthalmol       Date:  2006-08-02       Impact factor: 5.258

Review 5.  Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.

Authors:  J A Sivak-Callcott; D M O'Day; J D Gass; J C Tsai
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

6.  Proper method for calculating average visual acuity.

Authors:  J T Holladay
Journal:  J Refract Surg       Date:  1997 Jul-Aug       Impact factor: 3.573

7.  Bevacizumab as adjuvant for neovascular glaucoma.

Authors:  Julia Beutel; Swaantje Peters; Matthias Lüke; Sabin Aisenbrey; Peter Szurman; Martin S Spitzer; Efdal Yoeruek; Salvatore Grisanti
Journal:  Acta Ophthalmol       Date:  2009-09-20       Impact factor: 3.761

8.  Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.

Authors:  Yoshiaki Saito; Tomomi Higashide; Hisashi Takeda; Shinji Ohkubo; Kazuhisa Sugiyama
Journal:  Acta Ophthalmol       Date:  2009-09-23       Impact factor: 3.761

9.  Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.

Authors:  Naris Kitnarong; Panida Chindasub; Ankana Metheetrairut
Journal:  Adv Ther       Date:  2008-05       Impact factor: 3.845

10.  Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.

Authors:  Taku Wakabayashi; Yusuke Oshima; Hirokazu Sakaguchi; Yasushi Ikuno; Atsuya Miki; Fumi Gomi; Yasumasa Otori; Motohiro Kamei; Shunji Kusaka; Yasuo Tano
Journal:  Ophthalmology       Date:  2008-04-28       Impact factor: 12.079

View more
  4 in total

1.  Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma.

Authors:  Jin-Tao Sun; Hai-Jing Liang; Meng An; Da-Bo Wang
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

Review 2.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

3.  Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage.

Authors:  Xiu-Juan Li; Xiao-Peng Yang; Qiu-Ming Li; Yu-Ying Wang; Xiao-Bei Lyu
Journal:  Chin Med J (Engl)       Date:  2015-08-05       Impact factor: 2.628

4.  Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.

Authors:  Yaoyao Sun; Yong Liang; Peng Zhou; Huijuan Wu; Xianru Hou; Zeqin Ren; Xiaoxin Li; Mingwei Zhao
Journal:  BMC Ophthalmol       Date:  2016-08-30       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.